Ellen Donnelly
Chief Executive Officer at ABLIVA AB
Ellen Donnelly active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ALZECURE PHARMA AB | Director/Board Member | 31/12/2017 | - |
| Independent Dir/Board Member | 31/12/2017 | - | |
| MODUS THERAPEUTICS HOLDING AB | Director/Board Member | 31/12/2019 | - |
| Independent Dir/Board Member | 31/12/2019 | - | |
| Chief Executive Officer | - | 31/12/2019 | |
| ABLIVA AB | Chief Executive Officer | 02/02/2021 | - |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Director/Board Member | 31/12/2018 | - |
| Chief Executive Officer | 31/12/2015 | 31/12/2018 |
Career history of Ellen Donnelly
Former positions of Ellen Donnelly
| Companies | Position | Start | End |
|---|---|---|---|
Juvenescence Ltd.
 Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Corporate Officer/Principal | - | - |
Training of Ellen Donnelly
| Yale School of Medicine | Doctorate Degree |
Statistics
International
| Sweden | 5 |
| United Kingdom | 2 |
| United States | 2 |
Operational
| Director/Board Member | 3 |
| Chief Executive Officer | 3 |
| Independent Dir/Board Member | 2 |
Sectoral
| Health Technology | 5 |
| Finance | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| ALZECURE PHARMA AB | Health Technology |
| MODUS THERAPEUTICS HOLDING AB | Health Technology |
| ABLIVA AB | Health Technology |
| Private companies | 2 |
|---|---|
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Finance |
- Stock Market
- Insiders
- Ellen Donnelly
- Experience
